Skip to main content
Premium Trial:

Request an Annual Quote

SAEC, Duke to Collaborate on Rare Variants, Adverse Events Research

NEW YORK (GenomeWeb News) – Duke University's Center for Human Genome Variation and the International Serious Adverse Events Consortium plan to collaborate on research into the role of rare genetic variants in a drug-induced adverse event involving an antipsychotic drug called clozapine, SAEC announced today.

Through the collaboration, researchers hope to find rare genetic variants that can be used to predict an individual's risk of a condition called clozapine-induced agranulocytosis, or CIA, which leads to an inability for a person's bone marrow to produce enough white blood cells, decreasing their immune response.

The team plans to expand on published data on associations between the chromosome 6 HLA region and CIA using a whole-genome sequencing approach. They will reportedly use CIA cohort materials and data provided to SAEC by Clinical Data division PGx Health.

Clozapine is often used to treat schizophrenia patients, particularly those who don't respond to other drug treatments. But because it's estimated that the antipsychotic causes CIA in around two percent of individuals taking it, the drug is available through a Food and Drug Administration sanctioned surveillance system called the Clozapine Patient Management System. As part of this program, individuals taking clozapine have their white cells checked weekly before getting their supply of the drug.

"For many patients clozapine is the most effective drug available, but its use is constrained by the possibility of this serious adverse event requiring intrusive monitoring programs," project leader David Goldstein, director of Duke's Center for Human Genome Variation, said in a statement. "We hope that understanding the genetics of CIA will not only reduce its occurrence, but also allow wider use of clozapine."

Duke psychiatry researcher Anna Need is co-managing the collaboration between Duke University and SAEC, an international, non-profit research consortium spawned by the global pharmaceutical industry.

"By researching the genetics of drug-induced CIA, we hope to further our understanding into the genetics of immunologically mediated adverse drug responses," SAEC Chairman Arthur Holden said in a statement. "Our collaboration with Duke University's Center for Human Genome Variation represents our first pilot to use whole-genome sequencing technology to better understand the role of rare genetic variation in such event."

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.